The economic impact of rapid Candida species identification by T2Candida among high-risk patients.

Abstract

INTRODUCTION This study estimates the cost-effectiveness and hospital budget impact of rapid candidemia identification using T2Candida, a novel diagnostic panel with same-day species-specific results. MATERIALS & METHODS A 1-year decision-tree model estimates hospital costs (2013 US$) and effects (candidemia-related deaths) for faster diagnostics versus blood culture (BC), accounting for disease prevalence, distribution of Candida species, test characteristics (sensitivity/specificity/time to result), antifungal medication and differential length-of-stay and mortality by appropriate treatment timing. RESULTS The model estimates a hospital with 5100 annual high-risk patients could possibly save $5,858,448 with T2Candida versus BC, a 47.6% decrease in candidemia diagnosis and treatment budget ($1149/patient tested), while averting 60.6% of candidemia-related mortality. CONCLUSION Hospitals may observe lower candidemia-related inpatient costs and mortality with rapid Candida diagnosis.

DOI: 10.2217/fmb.15.29

Cite this paper

@article{Bilir2015TheEI, title={The economic impact of rapid Candida species identification by T2Candida among high-risk patients.}, author={Sara Pinar Bilir and Cheryl P. Ferrufino and Michael A. Pfaller and Julie Munakata}, journal={Future microbiology}, year={2015}, volume={10 7}, pages={1133-44} }